MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

Boston Scientific Corp.

Suletud

SektorTervishoid

101.15 2.18

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

98.57

Max

101.66

Põhinäitajad

By Trading Economics

Sissetulek

-138M

562M

Müük

352M

4.6B

P/E

Sektori keskmine

74.864

57.333

Aktsiakasum

0.7

Kasumimarginaal

12.322

Töötajad

53,000

EBITDA

-41M

1B

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+18.99% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

23. juuli 2025

Turustatistika

By TradingEconomics

Turukapital

-14B

138B

Eelmine avamishind

98.97

Eelmine sulgemishind

101.15

Tehniline skoor

By Trading Central

Kindlus

Strong Bullish Evidence

Boston Scientific Corp. Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

23. apr 2025, 12:16 UTC

Tulu
Suurimad hinnamuutused turgudel

Boston Scientific Shares Higher on Rosy Outlook, 1Q Beats

3. märts 2025, 12:35 UTC

Omandamised, ülevõtmised, äriostud

Boston Scientific to Buy Rest of SoniVie for Initial $360 Million

5. veebr 2025, 12:23 UTC

Tulu

Boston Scientific 4Q Profit Up on Strong Cardio Device Sales

23. apr 2025, 10:32 UTC

Tulu

Boston Scientific Sees 2Q Reported Sales Up 17.5%-19.5%, Organic Sales Up 13%-15% >BSX

23. apr 2025, 10:31 UTC

Tulu

Boston Scientific Sees 2025 Reported Sales Up 15%-17%, Organic Sales Up 12%-14% >BSX

23. apr 2025, 10:30 UTC

Tulu

Boston Scientific 1Q EPS 45c >BSX

23. apr 2025, 10:30 UTC

Tulu

Boston Scientific 1Q Adj EPS 75c >BSX

23. apr 2025, 10:30 UTC

Tulu

Boston Scientific Sees FY Adj EPS $2.87-Adj EPS $2.94 >BSX

23. apr 2025, 10:30 UTC

Tulu

Boston Scientific 1Q Sales $4.66B >BSX

23. apr 2025, 10:30 UTC

Tulu

Boston Scientific Sees 2Q Adj EPS 71c-Adj EPS 73c >BSX

23. apr 2025, 10:30 UTC

Tulu

Boston Scientific Sees 2Q EPS 45c-EPS 47c >BSX

23. apr 2025, 10:30 UTC

Tulu

Boston Scientific 1Q Organic Sales Up 18.2% >BSX

23. apr 2025, 10:30 UTC

Tulu

Boston Scientific Sees FY EPS $1.86-EPS $1.93 >BSX

3. märts 2025, 11:59 UTC

Omandamised, ülevõtmised, äriostud

Boston Scientific to Pay Up to Additional $180 Million Upon Achievement of Regulatory Milestone >BSX

3. märts 2025, 11:58 UTC

Omandamised, ülevõtmised, äriostud

Boston Scientific to Buy Rest of SoniVie for Initial $360 Million >BSX

3. märts 2025, 11:58 UTC

Omandamised, ülevõtmised, äriostud

Boston Scientific Announces Agreement To Acquire SoniVie Ltd. >BSX

5. veebr 2025, 21:33 UTC

Tulu

How Boston Sci Leaned On Its New Heart Device For A Fourth-Quarter Beat -- IBD

5. veebr 2025, 15:20 UTC

Tulu

How Boston Sci Leaned On Its New Heart Device For A Fourth-Quarter Beat -- IBD

5. veebr 2025, 11:39 UTC

Tulu

Boston Scientific Sees 1Q Organic Sales Up 14%-16% >BSX

5. veebr 2025, 11:39 UTC

Tulu

Boston Scientific Sees 1Q Sales Up 17%-19% >BSX

5. veebr 2025, 11:38 UTC

Tulu

Boston Scientific Sees 2025 Organic Sales Up 10%-12% >BSX

5. veebr 2025, 11:38 UTC

Tulu

Boston Scientific Sees 2025 Sales Up 12.5%-14.5% >BSX

5. veebr 2025, 11:37 UTC

Tulu

Boston Scientific 4Q Organic Sales Up 19.5% >BSX

5. veebr 2025, 11:37 UTC

Tulu

Boston Scientific 4Q Adj EPS 70c >BSX

5. veebr 2025, 11:37 UTC

Tulu

Boston Scientific Sees FY EPS $1.86-EPS $1.93 >BSX

5. veebr 2025, 11:37 UTC

Tulu

Boston Scientific 4Q Sales $4.56B >BSX

5. veebr 2025, 11:37 UTC

Tulu

Boston Scientific Sees FY Adj EPS $2.80-Adj EPS $2.87 >BSX

5. veebr 2025, 11:37 UTC

Tulu

Boston Scientific Sees 1Q Adj EPS 66c-Adj EPS 68c >BSX

5. veebr 2025, 11:37 UTC

Tulu

Boston Scientific Sees 1Q EPS 43c-EPS 45c >BSX

5. veebr 2025, 11:37 UTC

Tulu

Boston Scientific 4Q EPS 38c >BSX

Võrdlus sarnastega

Hinnamuutus

Boston Scientific Corp. Prognoos

Hinnasiht

By TipRanks

18.99% tõus

12 kuu keskmine prognoos

Keskmine 120.35 USD  18.99%

Kõrge 135 USD

Madal 110 USD

Põhineb 23 Wall Streeti analüütiku instrumendi Boston Scientific Corp. 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

23 ratings

22

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

95.25 / 102.37Toetus ja vastupanu

Lühikene perspektiiv

Strong Bullish Evidence

Keskpikk perspektiiv

Strong Bearish Evidence

Pikk perspektiiv

No Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Boston Scientific Corp.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.